Top Pharmaceutical Companies in Boston, MA (135)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue has risen at a steady mid- to high-single-digit pace—FY2025 grew 8.3% on a normalized basis, with FY2026 Q1 and Q2 up 7.7% and 7.3% respectively, alongside 3.8% active-customer growth. Management also raised its FY2026 net sales outlook, pointing to continued expansion.
Customer Loyalty & Retention: Autoship sales increased 9.3% in Q2 FY2026 to about $2.82 billion and represented 84.6% of total sales, supporting predictable, repeat purchasing. Sales per active customer also edged up to $602, indicating deepening engagement.
Profitability: Adjusted EBITDA climbed 23.7% in Q2 FY2026 to $226.7 million with a 6.8% margin, and net income rose year over year. These gains indicate improving operating earnings alongside growth.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.
Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.
Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.
Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.
Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
ProcDNA is a global analytics and technology consulting firm dedicated to delivering exceptional commercial analytics and technology solutions to the life sciences and healthcare sectors. Established in 2020, the company leverages a blend of design thinking, advanced data analytics, and AI to solve complex business challenges, transform data into commercial intelligence, and help pharmaceutical and biotechnology organizations achieve their goals...
Lyra Therapeutics is a clinical-stage biotechnology company developing long-acting, locally delivered anti-inflammatory implants to treat chronic rhinosinusitis (CRS). The company designs bioabsorbable drug-eluting matrices that release steroid therapy directly to sinonasal tissues for sustained relief, advancing lead candidates (LYR-210 and LYR-220) through late-stage clinical trials and pursuing commercialization and strategic alternatives to benefit CRS patients.
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
Advancing knowledge to improve lives.™ We are a global strategic partner with decades of experience across the entire life sciences product lifecycle. We excel in providing our clients with unique insights and efficiencies to support them in their journey to improve health outcomes and ultimately the quality of people’s lives. By connecting our full suite of products and services from scientific...
Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic...
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped...
Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing...
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L’Aquila, with an...
Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some...
Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. ?????????? ????????? ???? ????????? Excelra’s interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and...
Mariana Oncology, a Novartis company, is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Mariana is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The...
PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in The United States and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with...
BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several...
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused...
Vertex Pharmaceuticals's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials depict Vertex as a leader with near‑dominance in cystic fibrosis and first‑mover approvals in CRISPR‑based gene editing. This is supported by broad real‑world CF impact and landmark authorizations for Casgevy.
Strong Revenue Growth: Reported year‑over‑year revenue growth in 2025 and raised guidance for 2026 indicate ongoing momentum. Quarterly performance aligned with or exceeded guidance during the year, underscoring execution against growth plans.
Diversified Revenue Streams: Early contributions in 2025 from Alyftrek, Journavx, and Casgevy, with management signaling higher non‑CF revenues in 2026, show a broadening base beyond CF. Guidance highlighting non‑CF contribution points to increasing mix diversification over the near term.
